=Alder Biopharmaceuticals (ALDR) to be acquired by H. Lundbeck (HLUYY) for $18.00/share

Alder BioPharmaceuticals to be acquired by H. Lundbeck A/S (HLUYY) for $18.00/share in cash + CVR
Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Alder, whereby Alder stockholders will be offered an upfront payment for USD 18.00 per share in cash, along with one non-tradeable Contingent Value Right (CVR) that entitles them to an additional USD 2.00 per share upon approval of eptinezumab by the European Medicines Agency (EMA), representing a total potential consideration of USD 20.00 per share. The transaction is valued at up to USD 1.95 billion (approximately DKK 13 billion) net of cash, on a fully diluted basis.